Mikhael Ehab M, Hassali Mohamed A, Hussain Saad A, Shawky Nizar
Department of social and administrative Pharmacy, College of Pharmacy, Universiti Sains Malaysia, Penang, Malaysia.
Department of clinical pharmacy, College of Pharmacy, University of Baghdad, Baghdad-Iraq.
J Pharm Bioallied Sci. 2020 Jul-Sep;12(3):262-268. doi: 10.4103/jpbs.JPBS_190_19. Epub 2020 Jul 18.
The current trend for determining the effectiveness of new treatment or services provided for diabetes mellitus (DM) patients is based on assessing the improvement in both glycemic control and the patient quality of life. Many scales have been developed to assess quality of life among DM patients, but unfortunately, no one can be considered as gold standard. Therefore, this study aimed to develop and validate a brief and specific scale to assess quality of life among Iraqi type 2 DM patients.
An extensive literature review was done using Google-Scholar and PubMed to find out scales that utilized to assess quality of life among DM patients. Four relevant scales, three diabetes specific and one general, were selected. The selected scales were carefully evaluated to find out domains that are commonly used to assess quality of life and then the items within the selected domains were reviewed to choose relevant and comprehensive items for Iraqi type 2 DM patients. Ten items were selected to formulate the quality of life scale for Iraqi DM patients (QOLSID). The content validity of QOLSID was established via an expert panel. For concurrent validity QOLSID was compared to glycosylated hemoglobin (HbA1C). For psychometric evaluation, a cross sectional study for 103 type 2 DM patients was conducted at the National Diabetes Center, Iraq. Test-retest reliability was measured by re-administering QOLSID to 20 patients 2-4 weeks later.
The internal consistency of the QOLSID was 0.727. All items had a corrected total-item correlation above 0.2. There was a negative significant correlation between QOLSID score and the HbA1C level (-0.518, P = 0.000). A significant positive correlation was obtained after re-testing (0.967, P = 0.000).
The QOLSID is a reliable and valid instrument that can be used for assessing quality of life among Iraqi type 2 DM patients.
目前确定为糖尿病(DM)患者提供的新治疗方法或服务有效性的趋势是基于评估血糖控制和患者生活质量的改善情况。已经开发了许多量表来评估糖尿病患者的生活质量,但遗憾的是,没有一个可以被视为金标准。因此,本研究旨在开发并验证一个简短且特定的量表,以评估伊拉克2型糖尿病患者的生活质量。
使用谷歌学术和PubMed进行了广泛的文献综述,以找出用于评估糖尿病患者生活质量的量表。选择了四个相关量表,三个是糖尿病特异性量表,一个是通用量表。对所选量表进行了仔细评估,以找出常用于评估生活质量的领域,然后对所选领域内的项目进行审查,为伊拉克2型糖尿病患者选择相关且全面的项目。选择了10个项目来制定伊拉克糖尿病患者生活质量量表(QOLSID)。通过专家小组确定了QOLSID的内容效度。为了进行同时效度评估,将QOLSID与糖化血红蛋白(HbA1C)进行了比较。为了进行心理测量评估,在伊拉克国家糖尿病中心对103名2型糖尿病患者进行了横断面研究。通过在2-4周后对20名患者重新施用QOLSID来测量重测信度。
QOLSID的内部一致性为0.727。所有项目的校正后总项目相关性均高于0.2。QOLSID得分与HbA1C水平之间存在显著负相关(-0.518,P = 0.000)。重新测试后获得了显著正相关(0.967,P = 0.000)。
QOLSID是一种可靠且有效的工具,可用于评估伊拉克2型糖尿病患者的生活质量。